Naringenin neutralises oxidative stress and nerve growth factor discrepancy in experimental diabetic neuropathy

Al‐Rejaie, Salim S.; Aleisa, Abdulaziz M.; Abuohashish, Hatem M.; Parmar, Mihir; Ola, Mohammad Shamsul; Al-Hosaini, Abdulaziz A.; Ahmed, Mohammed M.

doi:10.1179/1743132815y.0000000079

Cited by 84 publications

(48 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Secondary risk factors are smoking and prediabetes [1,21,60,63]. Platelet activation [79][80][81][82], oxidative stress [65][66][67][68][69][70][71][72][73][74], low vitamin D [83,84], insulin resistance [58], and genetic factors [100][101][102][103][104][105][106] play another supplementary role, but, for the time being, there are limited options for intervention. A suggestion for targeting insulin resistance originates from the study by Pop-Busui et al, showing that reduced incident DSPN is less frequent in T2D patients receiving insulin-sensitizing oral agents (66%) than in those receiving insulinproviding treatment (66% vs. 72%, respectively, p = 0.02) [155].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015

2015

View full text Add to dashboard Cite

■ AbstractDistal symmetric sensorimotor polyneuropathy (DSPN) is the most common neurological manifestation in diabetes. Major risk factors of DSPN include diabetes duration, hyperglycemia, and age, followed by prediabetes, hypertension, dyslipidemia, and obesity. Height, smoking, insulin resistance, hypoinsulinemia, and others represent an additional risk. Importantly, hyperglycemia, hypertension, dyslipidemia, obesity, and smoking are modifiable. Stringent glycemic control has been shown to be effective in type 1, but not to the same extent in type 2 diabetes. Antilipidemic treatment, especially with fenofibrate, and multi-factorial intervention have produced encouraging results, but more experience is necessary. The major comorbidities of DSPN are depression, autonomic neuropathy, peripheral artery disease, cardiovascular disease, nephropathy, retinopathy, and medial arterial calcification. Knowledge of risk factors and comorbidities has the potential to enrich the therapeutic strategy in clinical practice as part of the overall medical care for patients with neuropathy. This article provides an updated overview of DSPN risk factors and comorbidities.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Experimental evidence suggests that oxidative stress is connected with DSPN [65][66][67][68]. Numerous studies have reported associations between systemic markers of oxidative stress and DSPN in diabetic patients.…”

Section: Oxidative Stressmentioning

confidence: 99%

Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015

2015

View full text Add to dashboard Cite

show abstract

“…[174][175][176][177][178][179][180] Due to their higher potential activity in many chronic diseases, they are widely used to prepare novel beverages. However, due to the limited oral bioavailability and stability of those compounds, alternative nano-based delivery technologies have been recently studied to assess their efficacy.…”

Section: Nano-naringeninmentioning

confidence: 99%

Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status

Ganesan¹,

Arulselvan²,

Choi³

2017

IJN

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is a major chronic disease that is prevalent worldwide, and it is characterized by an increase in blood glucose, disturbances in the metabolism, and alteration in insulin secretion. Nowadays, food-based therapy has become an important treatment mode for type 2 diabetes, and phytobioactive compounds have gained an increasing amount of attention to this end because they have an effect on multiple biological functions, including the sustained secretion of insulin and regeneration of pancreatic islets cells. However, the poor solubility and lower permeability of these phyto products results in a loss of bioactivity during processing and oral delivery, leading to a significant reduction in the bioavailability of phytobioactive compounds to treat T2DM. Recently, nanotechnological systems have been developed for use as various types of carrier systems to improve the delivery of bioactive compounds and thus obtain a greater bioavailability. Furthermore, carrier systems in most nanodelivery systems are highly biocompatible, with nonimmunologic behavior, a high degree of biodegradability, and greater mucoadhesive strength. Therefore, this review focuses on the various types of nanodelivery systems that can be used for phytobioactive compounds in treating T2DM with greater antidiabetic effects. There is also additional focus on improving the effects of various phytobioactive compounds through nanotechnological delivery to ensure a highly efficient treatment of type 2 diabetes.

show abstract

“…Further, treatment of STZ-induced diabetic rats with 50 and 100 mg/kg/day naringenin (orally for eight weeks) reversed chemical and thermal hyperalgesia and decreased hyperglycemia, as well as restored SOD activity [55]. Al-Rejaje et al demonstrated that naringenin treatment (25 and 50 mg/kg/day) significantly decreased the level of oxidative stress biomarkers and increased NGF in sciatic nerves of STZ-induced diabetic rats [56]. …”

Section: Effect Of Flavonoids On Neuronal Cell Death and Dysfunctionmentioning

confidence: 99%

Bioactive Compounds and Their Neuroprotective Effects in Diabetic Complications

2016

Nutrients

View full text Add to dashboard Cite

Hyperglycemia, hyperlipidemia and impaired insulin signaling during the development of diabetes can cause diabetic complications, such as diabetic neuropathy, resulting in significant morbidity and mortality. Although various therapeutics are available for the treatment of diabetic neuropathy, no absolute cure exists, and additional research is necessary to comprehensively understand the underlying pathophysiological pathways. A number of studies have demonstrated the potential health benefits of bioactive compounds, i.e., flavonoids and vitamins, which may be effective as supplementary treatments for diabetes and its complications. In this review, we highlight the most recent reports about the mechanisms of action of bioactive compounds (flavonoids and vitamins) possessing potential neuroprotective properties in diabetic conditions. Additional clinical studies are required to determine the appropriate dose and duration of bioactive compound supplementation for neuroprotection in diabetic patients.

show abstract

Naringenin neutralises oxidative stress and nerve growth factor discrepancy in experimental diabetic neuropathy

Abstract: We suggest that neuro-protective effect of NG molecules in sciatic nerve of diabetic rats, through its anti-diabetic as well as antioxidant and anti-inflammatory properties.

Cited by 84 publications

References 47 publications

Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015

Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015

Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status

Bioactive Compounds and Their Neuroprotective Effects in Diabetic Complications

Contact Info

Product

Resources

About

Naringenin neutralises oxidative stress and nerve growth factor discrepancy in experimental diabetic neuropathy

Abstract: We suggest that neuro-protective effect of NG molecules in sciatic nerve of diabetic rats, through its anti-diabetic as well as antioxidant and anti-inflammatory properties.

Cited by 84 publications

References 47 publications

Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015

Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015

Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus &ndash; current status

Bioactive Compounds and Their Neuroprotective Effects in Diabetic Complications

Contact Info

Product

Resources

About

Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status